AbbVie to invest $1.4 billion in new 185-acre manufacturing campus in Durham, North Carolina

AbbVie announced a $1.4 billion investment to build a large manufacturing campus in Durham, North Carolina.

The 185-acre site will focus on producing small-volume parenteral medicines such as vials and prefilled syringes for its immunology, neuroscience and oncology portfolios.

The company expects to hire about 734 staff, including engineers, scientists, production workers and lab technicians, over the next four years.

Construction is slated to start this year with completion targeted for the end of 2028, and the facility will incorporate artificial-intelligence tools to aid production.

The project marks AbbVie’s first major investment in North Carolina and is part of its broader $100 billion commitment to U.S. research, development and manufacturing over the next decade.